Reformulating influenza vaccines annually against dominant circulating strains leads to variable protective efficacy and is unlikely to protect against novel influenza viruses with pandemic potential. Thus, there is a great need for a vaccine that provides “universal” protection against influenza viruses.
The National Institutes of Health (NIH) has a Technology Transfer opportunity available for a virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes.
The technology has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes, further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.
Read more about this tech transfer opportunity or contact Elizabeth Pitts, Ph.D. at 240-669-5299 or email@example.com.
Source: National Institutes of Health, adapted.